Latest news

• Novartis files CAR-T therapy CTL109 in Europe

  as follow-up indication diffuse large B-cell lymphoma (DLBCL) which it submitted to the FDA last month. ... Kite was the first to file its new therapy in Europe, seeking approval in August for DLBCL, transformed follicular lymphoma (TFL), and primary

• Roche's Actemra/RoActemra receives new European approval

  Gazyvaro approved for advanced follicular lymphoma. Meanwhile, the European Commission has also licensed Roche’s Gazyvaro (obinutuzumab) for patients with previously untreated advanced follicular lymphoma. ... with follicular lymphoma who did not

• Bayer bags speedy US approval for lymphoma drug Aliqopa

  The FDA has approved Bayer's PI3K inhibitor Aliqopa, setting up a market showdown with Gilead Sciences' Zydelig in follicular lymphoma. ... Richard Pazdur, director of the FDA's Office of Haematology and Oncology Products, said: "For patients with

• Roche faces prospect of second Rituxan biosimilar in US

  Rituxan is used to treat blood cancers including non-Hodgkin's lymphoma and chronic lymphocytic leukaemia, as well as immunological diseases such as rheumatoid arthritis, and is Roche's biggest-selling ... at the drug's pharmacological profile in

• Kite starts EU trial of lead CAR-T therapy

  ZUMA-1 trial showed that in a heavily-treated population with refractory aggressive non-Hodgkin’s lymphoma (NHL) - with few treatment options - axi-cel achieved an overall response rate of 82%, ... Kite is currently enrolling adult patients with